We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
TTNP

Price
3.67
Stock movement down
-0.10 (-2.65%)
Company name
Titan Pharmaceuticals Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
3.36M
Ent value
-380.76K
Price/Sales
39.47
Price/Book
0.84
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-56.07%
1 year return
-46.73%
3 year return
-42.40%
5 year return
-51.71%
10 year return
-55.80%
Last updated: 2025-04-12

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

DIVIDENDS

TTNP does not pay dividends or no data was received

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales39.47
Price to Book0.84
EV to Sales-4.48

iO Charts is a Seeking Alpha partner

FINANCIALS

Per share

Loading...
Per share data
Current share count914.23K
EPS (TTM)-5.97
FCF per share (TTM)-9.19

Income statement

Loading...
Income statement data
Revenue (TTM)85.00K
Gross profit (TTM)-28.00K
Operating income (TTM)-7.13M
Net income (TTM)-5.46M
EPS (TTM)-5.97
EPS (1y forward)-

Margins

Loading...
Margins data
Gross margin (TTM)-32.94%
Operating margin (TTM)-8387.06%
Profit margin (TTM)-6424.71%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash4.09M
Net receivables38.00K
Total current assets4.35M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets4.35M
Accounts payable356.00K
Short/Current long term debt0.00
Total current liabilities356.00K
Total liabilities356.00K
Shareholder's equity3.99M
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-6.76M
Capital expenditures (TTM)2.00K
Free cash flow (TTM)-8.40M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-136.73%
Return on Assets-125.54%
Return on Invested Capital-136.73%
Cash Return on Invested Capital-210.24%

iO Charts is a Seeking Alpha partner

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open3.58
Daily high3.67
Daily low3.58
Daily Volume2K
All-time high1287000.00
1y analyst estimate7.00
Beta1.13
EPS (TTM)-5.97
Dividend per share-
Ex-div date17 Feb 2012
Next earnings date-

Downside potential

Loading...
Downside potential data
TTNPS&P500
Current price drop from All-time high-100.00%-12.89%
Highest price drop-100.00%-56.47%
Date of highest drop16 Jan 20259 Mar 2009
Avg drop from high-89.40%-11.07%
Avg time to new high115 days12 days
Max time to new high6164 days1805 days

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
TTNP (Titan Pharmaceuticals Inc) company logo
Marketcap
3.36M
Marketcap category
Small-cap
Description
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The company was founded in 1991 and is based in South San Francisco, California.
Employees
4
Investor relations
-
SEC filings
CEO
Sunil Bhonsle
Country
USA
City
South San Francisco
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...